Your email has been successfully added to our mailing list.

×
-0.00776699029126214 0 -0.0388349514563107 -0.0213980582524272 -0.0310679611650486 -0.0310679611650486 0.036893203883495 -0.0116504854368933
Stock impact report

Roche, AC Immune anti-Tau Alzheimer's drug fails trial [Reuters]

AC Immune SA (ACIU)  More Company Research Source: Reuters
Last ac immune sa earnings: 11/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
PDF Roche, AC Immune anti-Tau Alzheimer's drug fails trial By Reuters Staff 1 Min Read ZURICH (Reuters) - Swiss drugmaker Roche and partner AC Immune said their experimental anti-Tau Alzheimer’s disease drug semorinemab failed to slow cognitive decline in a trial, a fresh blow to efforts against the fatal dementia-causing disease. “Although we are disappointed by the topline results, we believe these data will contribute to the scientific understanding of the role of tau in this complex and difficult-to-treat disease,” Rachelle Doody, head of Roche’s neurodegeneration operations, said in a statement. [Read more]
Impact snapshot Event time: ACIU
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ACIU alerts
from News Quantified
Opt-in for
ACIU alerts

from News Quantified
Opt-in for
ACIU alerts

from News Quantified